Astorg has completed its acquisition of the global microbiology business from Thermo Fisher Scientific, establishing an independent company that will launch under a new brand later in 2026. The business provides diagnostic consumables and equipment for clinical, food safety, and pharmaceutical testing, serving more than 15,000 customers across over 100 countries with approximately 2,400 employees and 13 manufacturing and R&D sites worldwide. Dirk Bontridder has been appointed Chief Executive Officer, bringing over 25 years of leadership experience in life sciences and diagnostics, most recently as CEO of PerkinElmer. Astorg, a pan-European private equity firm with over €24 billion in assets under management, highlighted the transaction as part of its focused healthcare strategy and expertise in complex carve-outs.
Thermo Fisher Scientific IncThermo Fisher divests its microbiology business, reducing its portfolio.
Revvity Inc.Astorg completes acquisition, expanding its healthcare portfolio.
